Javier Ortega, Senior Medical Manager – Pivotal
1. Lipoprotein(A): From Biology to Clinical Development
1.1 Introduction
Lipoprotein(a) [Lp(a)] is a genetically determined, causal, and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS) [1] [2] [3]. First described by Kåre Berg in 1963, [4] Lp(a) has emerged as one of the most important, and until recently untreatable, targets of residual cardiovascular risk.
Approximately 1.5 billion people worldwide (roughly 20% of the global population) have elevated Lp(a) concentrations (≥125 nmol/L or ≥50 mg/dL) [1]. Despite decades of evidence establishing its causal role, Lp(a) has remained largely unaddressed in clinical practice because no approved pharmacological therapy has specifically targeted its reduction. This unmet need has now catalyzed an extraordinary wave of clinical research activity, with several novel agents, primarily RNA-based therapeutics, progressing through Phase 3 cardiovascular outcomes trials (CVOTs) [5] [6] [7].
The 2026 American College of Cardiology (ACC)/American Heart Association (AHA) Dyslipidemia Guidelines now assigns a Class I recommendation for universal Lp(a) screening in all adults, [1] a landmark shift that will substantially increase clinical demand for Lp(a)-lowering therapies. Lp(a) levels vary significantly across racial/ethnic groups. Black/African-descent populations have, on average, 2–3× higher Lp(a) levels than White European populations but have historically been underrepresented in cardiovascular clinical trials [3].
For Contract Research Organizations (CROs), the combination of a large patient population, along with novel therapeutics and growing regulatory demands for inclusivity, offers significant opportunities while introducing complex operational challenges.
1.2 Chemical Structure and Biochemistry
Lp(a) is a complex lipoprotein particle composed of a low-density lipoprotein (LDL)-like core containing cholesteryl esters, triglycerides, phospholipids, and free cholesterol, surrounded by a single apolipoprotein B-100 (apoB-100) molecule. Unlike LDL, Lp(a) is characterized by the presence of a distinct glycoprotein, apolipoprotein(a) [apo(a)], which is covalently linked to apoB-100 through a single disulfide bond at kringle IV subtype 9 [8] [9].
Apo(a) evolved from the plasminogen gene through duplication and remodeling. While plasminogen contains five kringle domains (KI–KV) and an active protease domain, apo(a) lacks KI–KIII but possesses ten subtypes of kringle IV (KIV₁–KIV₁₀), one copy of KV, and a catalytically inactive protease domain. KIV₂ is present in a variable number of identically repeated copies (1 to >40), creating a unique copy number variation that is the primary genetic determinant of plasma Lp(a) concentration. Smaller isoforms are associated with higher Lp(a) levels because larger apo(a) molecules are preferentially degraded intracellularly before secretion [8] [9].
Lp(a) assembly occurs on the hepatocyte surface or in the space of Disse, where newly synthesized apo(a) binds to apoB-100 through both noncovalent and covalent interactions. Lp(a) is the only apoB-containing lipoprotein that carries oxidized phospholipids (OxPL), covalently bound to apo(a) at KIV₁₀, which are central to its pathogenic properties [10]. Clearance mechanisms remain incompletely understood but may involve hepatic, renal, or combined pathways.
1.3 Pathophysiological Mechanisms
Lp(a) promotes cardiovascular disease through four interconnected mechanisms:
Atherogenesis
The LDL-like component of Lp(a) containing apoB is intrinsically atherogenic. Lp(a) enters the arterial intima and may be selectively retained through apo(a) binding to extracellular matrix proteins. Once oxidized, the LDL portion is avidly taken up by macrophages, generating foam cells and promoting plaque formation [11] [12].
Vascular Inflammation
Lp(a) is the principal carrier of OxPL in plasma. OxPL can act similarly to danger-associated molecular patterns (DAMPs) by activating innate immune receptors and driving vascular inflammation. Lp(a) upregulates endothelial adhesion molecules and cytokine expression, facilitates monocyte transmigration, and acts as a potent monocyte chemoattractant. Enhanced arterial wall inflammation has been demonstrated by ¹⁸F-fluorodeoxyglucose PET imaging in patients with elevated Lp(a) [13].
Calcification
Lp(a) and its components, apo(a), OxPL, and autotaxin, colocalize in diseased aortic valves adjacent to areas of calcification. Lp(a) upregulates procalcific and osteogenic genes in valvular interstitial cells and induces hydroxyapatite mineral deposition. Patients with elevated Lp(a) show enhanced ¹⁸F-NaF aortic valve uptake (representing active calcification), faster calcification progression on serial CT, and worse clinical outcomes [2] [14].
Prothrombotic Effects
Due to its structural homology with plasminogen, apo(a) can bind to fibrin and fibrinogen through its lysine-binding sites. This may inhibit plasminogen activation and plasmin-driven fibrinolysis, potentially promoting thrombus growth at sites of plaque rupture [3] [9]. However, the clinical importance of this mechanism is debated, as plasminogen is usually present in far higher concentrations than apo(a) except at very high Lp(a) levels.
1.4 Clinical Relevance and Epidemiology
1.4.1 Cardiovascular Risk
Epidemiological studies, genome-wide association studies, and Mendelian randomization analyses involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes. The risk relationship is dose-dependent [1] [11] [12] [15]:
| Lp(a) Level | Approx. Percentile | Relative ASCVD Risk vs. Median |
| ≥50 mg/dL (≥125 nmol/L) | ~80th | ~1.4× increased risk |
| ≥100 mg/dL (≥250 nmol/L) | ~95th | ~2× increased risk |
| ≥180 mg/dL (≥430 nmol/L) | ~99th | ~4× increased risk (comparable to HeFH) |
HeFH: heterozygous familial hypercholesterolemia. Risk estimates from Mendelian randomization analyses.
This risk is independent of LDL-C and other traditional cardiovascular risk factors, supporting Lp(a) as a genuinely additive risk dimension requiring separate clinical management [11] [15].
1.4.2 Disease Spectrum
Elevated Lp(a) is causally associated with myocardial infarction (MI), ischemic stroke, peripheral arterial disease, and calcific aortic valve stenosis [14][15]. Current evidence does not support Lp(a) as a causal risk factor for venous thromboembolism [15].
1.4.3 Ethnic Variation
Plasma Lp(a) levels vary markedly between populations. Levels are highest in individuals of African descent (approximately four times higher than in White populations), intermediate in South Asian, Latin American, and Middle Eastern groups, and lowest in East Asian and European populations [2] [3] [16]. Critically, the relative increase in ASCVD risk per unit rise in Lp(a) is consistent across all ancestries, supporting the use of a single clinical threshold globally, though absolute risk will be higher in populations with higher baseline levels [2] [3].
1.4.4 Genetic Determination
Lp(a) levels are >90% genetically determined, with minimal influence from diet, exercise, or lifestyle [9] [11]. Lp(a) follows an autosomal codominant inheritance pattern. This has two important practical implications: (1) a single measurement is generally sufficient for lifetime risk assessment, and (2) conventional lipid-lowering therapies (statins, ezetimibe) do not meaningfully reduce Lp(a) levels.
1.5 Lp(a) Measurement: Standards, Units, and Challenges
1.5.1 Screening Recommendations
The 2026 ACC/AHA Dyslipidemia Guidelines provide a Class I (Level of Evidence B-NR) recommendation for measurement of Lp(a) at least once in all adults for ASCVD risk assessment, ideally with the first lipid profile (fasting is not required) [1]. Additional recommendations include:
- Cascade testing: First-degree family members of individuals with high Lp(a) should be tested, particularly those with a personal or family history of premature ASCVD, premature aortic stenosis, or familial hypercholesterolemia [1] [2].
- Repeat measurement: Generally unnecessary given genetic determination, except post-menopause in women (Lp(a) increases ≈17% after age 50), or when secondary causes are suspected (kidney, liver, or thyroid disease; pregnancy; certain medications) [1] [2] [3].
Several major international cardiovascular societies, including the European Atherosclerosis Society (EAS) and the Canadian Cardiovascular Society (CCS), recommend measuring Lp(a) at least once in all adults, with a threshold of >50 mg/dL (125 nmol/L) to define elevated risk [2] [17].
1.5.2 The Complexity of Lp(a) Quantification
Accurate measurement of Lp(a) is technically demanding. The defining challenge is the extreme size polymorphism of apo(a), driven by a variable number of KIV₂ domain repeats, which causes molecular weights to range from 187 kDa to over 662 kDa [18][19].
This structural heterogeneity means that polyclonal antibodies cross-react with multiple KIV₂ repeats, systematically overestimating Lp(a) in individuals with large isoforms and underestimating it in those with small isoforms. As a result, the strength of the association between Lp(a) and cardiovascular risk has historically appeared inconsistent and has been underestimated [18] [20].
1.5.3 The Units Debate: mg/dL versus nmol/L
A critical practical issue is the ongoing transition from mass-based (mg/dL) to particle-based molar (nmol/L) units. Converting between units using a fixed factor of 2.5 is systematically inaccurate: it overestimates concentration for larger isoforms and underestimates it for smaller isoforms [18] [21].
Analysis from the Lp(a) HORIZON screening program across 14,247 patients demonstrated significant discordance between measured and converted nmol/L values, with direct practical consequences for patient eligibility determination in clinical trials [21]. Current National Heart, Lung, and Blood Institute (NHLBI) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) guidance supports universal adoption of nmol/L units, calibrated against World Health Organization (WHO)/IFCC SRM-2B reference material and, more recently, against the Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs reference measurement procedure based on liquid chromatography–mass spectrometry [1] [22].
1.5.4 Inter-Laboratory Variability and Standardization Imperatives
Inter-assay variability of 3.3%–69.1% across laboratories has been documented for Lp(a) measurement [19]. The consequences from this variability include inability to establish universal reference intervals, inconsistent clinical cut-off application, and impaired pharmacological efficacy assessment across studies [20] [23].
Pre-analytical factors, including sample stability, storage temperature, and interference from lipemia or hemolysis, further complicate assay performance [24]. Emerging technologies such as mass spectrometry-based methods hold promise for improved precision but are not yet widely implemented due to cost and complexity.
For CROs, these issues have direct operational implications (addressed in detail in Section 8.4).
1.6.1 Therapeutic Mechanisms
1.6 Clinical Development of Lp(a)-Lowering Therapies
Three distinct mechanistic approaches are currently in advanced clinical development [25] [26] [27]:
- Antisense oligonucleotides (ASOs): Targeting LPA mRNA in the hepatocyte nucleus, preventing apo(a) synthesis, conjugated to N-acetylgalactosamine (GalNAc) for hepatocyte-specific delivery.
- Small interfering RNA (siRNA): Targeting LPA mRNA in the hepatocyte cytosol via the RNA-induced silencing complex (RISC), GalNAc-conjugation provides extended duration of action due to RISC stability.
- Small molecule inhibitors: Block the extracellular binding of apo(a) to apoB-100, preventing Lp(a) particle assembly, orally administered.
1.6.2 Agents in Development
| Agent | Mechanism | Route/Frequency | Max Lp(a) Reduction | Phase | CVOT |
| Pelacarsen | ASO | SC monthly | ≈80% | 3 | Lp(a)HORIZON (NCT04023552) |
| Olpasiran | siRNA | SC every 12 weeks | ≈98% | 3 | OCEAN(a) (NCT05581303) |
| Lepodisiran | siRNA | SC once–twice yearly | ≈98% | 3 | ACCLAIM-Lp(a) (NCT06292013) |
| Zerlasiran | siRNA | SC 2–4× yearly | ≈98% | 2 | — |
| Muvalaplin | Small molecule | Oral daily | ≈65% | 2 | — |
SC: subcutaneous; ASO: antisense oligonucleotide; siRNA: small interfering RNA; CVOT: cardiovascular outcomes trial.
1.6.3 Ongoing Phase 3 Cardiovascular Outcomes Trials
Lp(a)HORIZON (pelacarsen, Novartis) [5]
- Population: 8,323 patients with established ASCVD and Lp(a) ≥70 mg/dL (≈149 nmol/L)
- Intervention: Pelacarsen 80 mg SC monthly vs. placebo
- Primary endpoint: composite of CV death, nonfatal MI, nonfatal stroke, and urgent coronary revascularization
- Duration: event-driven (≈993 events); estimated ≈6 years total follow-up
Novartis announced the results of this study in September 2026, pending presentation at medical conferences and publication in scientific journals. Pelacarsen, despite its ability to reduce Lp(a) levels, was not associated with a reduction in cardiovascular events in the study population.
OCEAN(a)-Outcomes (olpasiran, Amgen) [6]
- Population: 7,297 patients with established ASCVD and Lp(a) ≥200 nmol/L (≈94 mg/dL)
- Intervention: Olpasiran SC every 12 weeks vs. placebo
- Primary endpoint: composite of CV death, nonfatal MI, and urgent coronary revascularization6
- Estimated follow-up: ≈5 years (start December 2022 → primary completion March 2028)
ACCLAIM-Lp(a) (lepodisiran, Eli Lilly) [7]
- Population: ≈17,300 adults with elevated Lp(a) and either established ASCVD or at risk for a first CV event (broadest population of the three) and Lp(a) ≥175 nmol/L (≈82 mg/dL)
- Intervention: Lepodisiran SC (dosing frequency informed by Phase 2 data) vs. placebo
- Primary endpoint: composite of coronary heart disease (CHD) death, nonfatal MI, stroke, and urgent coronary revascularization7
- Estimated follow-up: ≈5 years (start March 2024 → primary completion March 2029)
A key question across all three trials is whether the magnitude of Lp(a) reduction, typically 80–98% with RNA-based agents, will translate into a clinically meaningful reduction in MACE. Estimates from Mendelian randomization suggests that an absolute Lp(a) reduction of ≈30–100 mg/dL (≈75–250 nmol/L) may be needed to achieve a 20% relative risk reduction, a target achievable with all current agents [28] [29].
1.6.4 Emerging Approaches
Additional strategies under investigation include oral PCSK9 inhibitors, cholesterol ester transfer protein (CETP) inhibitors, and gene editing technologies [30]. None of them have yet entered cardiovascular outcomes trials specifically designed to test the Lp(a)-lowering hypothesis. The Lp(a) field has also uniquely leveraged Mendelian randomization analyses to estimate required effect sizes and inform trial powering, a methodology that CROs advising sponsors on trial design should understand in both its strengths and limitations [29].
2. Strategic importance of LP(A) for contract research organizations (CRO)
2.1 The Lp(a) Opportunity Landscape
2.1.1 Market Size and Unmet Need
The Lp(a) therapeutic space represents one of the largest and most consequential opportunities in cardiovascular clinical development of the current decade. An estimated 1.5 billion people globally have elevated Lp(a) (≥125 nmol/L), making it one of the most prevalent genetically determined cardiovascular risk factors [1]. No approved Lp(a)-specific therapy exists, creating a first-in-class opportunity for multiple sponsors simultaneously.
The 2026 ACC/AHA universal screening recommendation will dramatically increase awareness, diagnosis, and treatment demand1. The addressable patient population spans primary and secondary prevention, CAVS (a disease with no approved pharmacological therapy) and special populations including chronic kidney disease and familial hypercholesterolaemia [2] [3].
2.1.1 Active Pipeline and Trial Volume
At least five distinct Lp(a)-lowering agents are in clinical development, with three concurrent Phase 3 CVOTs enrolling a combined ≈28,000 patients [5] [6] [7]. Multiple sponsors (Novartis, Amgen, Eli Lilly, Silence Therapeutics, and Ionis/Alnylam) are competing in this space, creating sustained demand for CRO services across all phases of development.
Beyond the current CVOTs, additional trials are anticipated in primary prevention (leveraging imaging surrogates such as coronary artery calcium scoring and CT angiography), CAVS, peripheral arterial disease, and special populations [26] [31].
2.1.2 Novel Therapeutic Modalities
The Lp(a) pipeline encompasses ASOs, siRNAs, small molecules, and potentially gene editing, each requiring specialized expertise in manufacturing oversight, regulatory strategy, pharmacovigilance, and clinical operations. GalNAc-conjugated nucleic acid therapeutics represent a rapidly growing modality class with implications far beyond Lp(a): experience gained in Lp(a) trials directly translates to the broader RNA therapeutics landscape (e.g., inclisiran for PCSK9 lowering TTR amyloidosis therapies, and others) [32] [33].
2.2 Operational Challenges and CRO Differentiators
2.2.1 Biomarker-Driven Patient Identification and Screening
Unlike many cardiovascular trials where eligibility is based on clinical history alone, Lp(a) trials require a biomarker-based eligibility screening step. This introduces several important challenges:
- Pre-screening logistics: Lp(a) is not part of standard lipid panels in most healthcare systems. CROs must develop efficient pre-screening strategies leveraging electronic health records (EHR), direct-to-consumer testing, or partnerships with diagnostic laboratories to identify eligible patients before formal screening visits.
- Screening failure rates: Because only ≈20% of the general population has elevated Lp(a) (≥125 nmol/L), and pivotal trials require even higher thresholds (e.g., ≥200 nmol/L for OCEAN(a)) [6], screening failure rates can be substantial. CROs capable of pre-identifying patients through EHR mining or registry partnerships will have a decisive competitive advantage.
- Assay variability: Inter-assay variability of up to 69% across laboratories means that Lp(a) values obtained during local pre-screening may not match central laboratory results [23]. CROs must ensure consistent use of validated isoform-insensitive assays, traceable to reference standards, and must train sites on proper sample handling (e.g., avoiding prolonged freezing, which can produce falsely low values).
- Stable biomarker leverage: Given that Lp(a) levels are >90% genetically determined, [9] a single prior Lp(a) measurement may validly identify eligible patients, reducing the burden of repeat screening visits. This property should be explicitly incorporated into pre-screening workflows and reflected in protocol eligibility criteria design.
2.2.2 Diversity and Representativeness
The Lp(a) field presents both an imperative and a scientific opportunity for diverse enrolment:
- Biological rationale: Lp(a) levels are highest in individuals of African descent (≈4× higher than in White populations) and elevated in South Asian populations [34]. These populations bear a disproportionate burden of Lp(a)-associated cardiovascular risk and stand to benefit most from targeted therapies. Their adequate representation is a scientific necessity, not merely an ethical aspiration.
- Regulatory expectations: The FDA’s diversity action plan requirements (Food and Drug Omnibus Reform Act, 2022) mandate that sponsors submit enrolment targets by race, ethnicity, sex, and age. CROs must be prepared to develop and execute diversity action plans, monitor enrolment demographics in real time, and implement mitigation strategies for under-representation [35].
- Real-world testing gap: Despite higher disease burden, Lp(a) testing rates in Black and other minority populations remain lower than in White populations. In one large US health system analysis, only 1% of patients underwent Lp(a) testing, with significant variation by race/ethnicity [36].
- Operational strategies: Successful diverse enrolment requires community-engaged recruitment, culturally sensitive and multilingual trial materials, decentralized trial elements (home nursing, telemedicine), and deliberate site selection in communities with high Lp(a) prevalence.
2.2.3 Long-Duration, Event-Driven Trial Design and Endpoint Selection
The current Lp(a) CVOTs are large, long-duration, event-driven trials (e.g., Lp(a)HORIZON: ≈6 years, 993 events required) [5][6][7]. This creates distinctive operational demands:
- Patient retention: Maintaining engagement over multi-year follow-up, particularly with subcutaneous injectable therapies administered monthly to semi-annually.
- Vital status tracking: Systematic procedures for tracking mortality in populations with elevated baseline cardiovascular risk, across multinational sites, must be embedded in the trial operations manual.
- Event adjudication: Robust Clinical Event Committee (CEC) infrastructure for adjudicating composite MACE endpoints (cardiovascular death, MI, stroke, revascularization) is essential, aligned to ACC/AHA key data element definitions.
- Adaptive monitoring: Real-time event accrual tracking to inform interim analyses and study duration projections, with pre-specified stopping rules for benefit, futility, and harm.
- Background therapy evolution: Over multi-year trials, standard-of-care therapies may change (new LDL-C-lowering agents, anti-inflammatory therapies), requiring protocol flexibility and careful documentation of concomitant medications.
Beyond MACE, aortic valve stenosis represents an emerging and scientifically compelling endpoint:
CAVS is causally linked to Lp(a), with one in seven CAVS cases attributed to elevated Lp(a) [2] [14]. Proposed surrogate endpoints for CAVS trials include echocardiographic aortic valve area progression and ¹⁸F-NaF valve uptake on PET-CT. However, CAVS trials present particular challenges: longer required follow-up, specialized echocardiography core laboratory expertise, and the important lesson from failed statin trials in CAVS that patient enrichment for Lp(a) elevation (not generic lipid lowering) is the key eligibility determinant [37].
A key regulatory question is whether the magnitude of Lp(a) reduction will ultimately be accepted as a surrogate endpoint supporting accelerated approval, prior to full MACE outcomes data. CROs should proactively engage with sponsors on regulatory strategy and maintain close familiarity with evolving EMA and FDA scientific advice guidance in this area.
2.2.4 Central Laboratory and Biomarker Expertise
Lp(a) measurement is technically complex and not yet fully standardized globally. CROs with strong central laboratory capabilities can differentiate themselves substantially by [19] [20] [22] [23]:
- Deploying validated, isoform-insensitive Lp(a) assays with multi-calibrator systems (ideally ≥5 different isoform sizes) standardized against WHO/IFCC reference material.
- Reporting exclusively in nmol/L, with clear documentation of conversion practices where dual-unit reporting is required by local regulations.
- Maintaining strict pre-analytical Standard Operating Procedures (cold chain management, defined sample handling timelines, and freeze-thaw minimization protocols) to control the major sources of pre-analytical variability.
- Providing pharmacodynamic Lp(a) monitoring alongside clinical endpoint data, to document treatment effect (both absolute and percentage Lp(a) reduction) as a key secondary endpoint in all CVOTs.
- Managing the evolving standardization landscape as the CDC Clinical Standardization Programs reference measurement procedure becomes the global benchmark.
2.2.5 RNA Therapeutic Operations
The dominant therapeutic modalities in Lp(a) trials, ASOs and siRNAs, have distinctive pharmacological properties with direct operational implications:
- Infrequent dosing schedules: Monthly to semi-annual subcutaneous administration reduces site visit burden but requires robust patient engagement and retention strategies across extended follow-up periods [5] [6] [7].
- GalNAc-conjugated delivery: Hepatocyte-specific targeting shapes the safety monitoring profile. Liver function testing (ALT, AST, bilirubin) should be pre-specified in protocols at appropriate intervals, with clear stopping rules [26].
- Extended pharmacodynamic duration: Particularly for lepodisiran (potentially dosed once or twice yearly) adapted pharmacodynamic sampling schedules are required, and washout considerations must be explicitly addressed in crossover designs [38] [39].
- Injection site reaction monitoring: Systematic capture of injection site reactions, immunogenicity testing, and standardized grading aligned with CTCAE (Common Terminology Criteria for Adverse Events) criteria should be embedded in safety monitoring plans.
- Cold chain logistics: ASO and siRNA products typically require controlled temperature storage and distribution. CROs must establish compliant cold chain management across global site networks.
2.2.6 Regulatory and Pharmacovigilance Considerations
CROs operating in the Lp(a) space must navigate a regulatory environment defined by novelty:
- First-in-class pathway: No Lp(a)-lowering drug has received regulatory approval. CROs must be prepared to navigate uncertainty regarding acceptable surrogate endpoints, required magnitude of Lp(a) reduction, and the evidentiary standard for cardiovascular benefit.
- Novel modality safety monitoring: Long-acting siRNAs (e.g., lepodisiran, with effects persisting months after a single dose) require extended pharmacovigilance windows, careful monitoring for delayed adverse effects, and immunogenicity surveillance programmes.
- Data Safety Monitoring Boards (DSMBs) and CECs: Independent DSMBs with pre-specified stopping rules and blinded CECs are mandatory operational requirements for all Lp(a) CVOTs [7].
- Class-specific safety signals for ASOs and siRNAs
Both antisense oligonucleotides (pelacarsen) and siRNA therapies (olpasiran, lepodisiran) carry class-level safety considerations that require specific pharmacovigilance attention: - Hepatotoxicity — liver enzyme monitoring (ALT/AST) is standard given hepatic targeting
- Thrombocytopenia — a known class effect of ASOs requiring platelet monitoring protocols
- Injection site reactions — systematic CTCAE-graded assessment required
- Renal function — ASOs accumulate in renal tissue; renal biomarkers warrant longitudinal monitoring
- Pharmacovigilance systems: ICH E2A/E2B-aligned serious adverse event reporting pathways must account for the complexity of cardiovascular events in elderly, multi-morbid trial populations across multinational sites.
2.3 Sites and Countries Selection Strategy
The combination of high Lp(a) eligibility thresholds, ethnic diversity requirements, and the need for experienced cardiovascular outcomes research sites makes country and site selection a strategic differentiator for CROs in this space. Key criteria include:
- Population Lp(a) prevalence: Countries and regions with high proportions of individuals of African and South Asian ancestry offer superior screening yield. Site networks in South Asia, sub-Saharan Africa, and among Black/African-American and South Asian communities in North America and Europe should be explicitly prioritized.
- Local assay availability: Sites in countries where validated, isoform-insensitive Lp(a) assays reporting in nmol/L are already in routine clinical use will have lower pre-screening barriers and higher eligibility confirmation rates.
- EHR integration capabilities: The ability to query historical Lp(a) results from electronic health records can dramatically improve pre-screening efficiency and reduce screen failure rates, a capability that should be assessed at feasibility site qualification.
- RNA therapeutic experience: Site familiarity with subcutaneous injectable investigational products, GalNAc-conjugated biologics, and extended pharmacovigilance protocols is essential for operational efficiency.
- Regulatory infrastructure: Countries with streamlined ethics review processes, established competent authority experience with cardiovascular outcomes trials, and national cardiovascular registries suitable for event rate estimation should be prioritized.
- Cardiovascular event rates: Event-driven trials require careful site selection to ensure adequate event accrual. Sites should be selected based on documented MACE event rates in their patient populations, informed by registry data where available.
2.4 Strategic Recommendations for CROs
Based on the analysis above, the following strategic priorities are recommended for CROs seeking to build or strengthen capabilities in the Lp(a) space:
- Invest in Lp(a) screening infrastructure. Develop partnerships with diagnostic laboratories, EHR-based patient identification platforms, and direct-to-consumer testing services to build pre-screened patient registries. This capability will be a decisive differentiator as multiple sponsors compete for the same patient population.
- Build RNA therapeutics operational expertise. The Lp(a) pipeline is dominated by ASO and siRNA modalities. CROs that develop deep competency in nucleic acid therapeutic development (including manufacturing oversight, cold chain logistics, immunogenicity monitoring, and extended pharmacovigilance) will be positioned for growth across the broader RNA therapeutics landscape.
- Prioritize diversity and community engagement. Given the disproportionate Lp(a) burden in African and South Asian populations, CROs should invest in community-engaged research infrastructure, culturally competent site staff training, multilingual trial materials, and decentralized trial capabilities to ensure representative enrolment and regulatory compliance.
- Develop central laboratory excellence in Lp(a) measurement. Standardization of Lp(a) assays is an evolving field. CROs with validated, isoform-insensitive platforms traceable to IFCC/CDC reference standards, and expertise in biomarker-driven trial operations, will be essential partners for sponsors navigating measurement variability.
- Prepare for expansion beyond secondary prevention. While current CVOTs focus on secondary prevention, the next wave of Lp(a) trials will target primary prevention, CAVS, and special populations. CROs should anticipate these trial designs (including imaging surrogate endpoint management and echocardiography core laboratory expertise) and develop relevant capabilities proactively.
- Leverage real-world evidence capabilities. As universal screening generates large-scale Lp(a) data, CROs with real world evidence capabilities can support post-marketing commitments, payer evidence generation, and health technology assessments, extending their value beyond the pivotal trial phase.
2.5 Conclusions
Lipoprotein(a) is at a critical inflection point. Decades of genetic and epidemiological research have firmly established its causal role as a cardiovascular risk factor affecting over a billion individuals worldwide. The simultaneous alignment of universal screening guidelines, multiple first-in-class therapies in advanced clinical development and growing regulatory expectations for diverse and representative trial populations creates a unique strategic moment in cardiovascular medicine.
For CROs, such as Pivotal, the Lp(a) field demands a distinctive and integrated competency set, spanning biomarker measurement science, biomarker-driven patient identification, RNA therapeutic operations, diverse enrolment strategies, endpoint design, and long-term event-driven trial management. None of these dimensions can be approached with generic cardiovascular trial capabilities alone.
Although the results of the first clinical trial (Horizon III) with pelacarsen (an ASO) did not show a reduction in CV events associated with the reduction of LP(a), it is necessary to wait for the publication of the results of this study and the completion of the other ongoing clinical trials (with siRNAs) to analyze in depth the relationship between Lp(a) reduction and cardiovascular events and to assess whether there is any subgroup of patients who could benefit from this therapy.
The readout of HORIZON, OCEAN(a), and ACCLAIM-Lp(a) will be landmark events not just for cardiovascular medicine, but for the broader field of genetically targeted therapy. CROs that invest now in the capabilities described in this paper will be best positioned to serve as the preferred operational partners for sponsors navigating one of the most consequential clinical development programs of this decade.
References
7. ClinicalTrials.gov. ACCLAIM-Lp(a): A Study of Lepodisiran. NCT06292013
35. Food and Drug Omnibus Reform Act of 2022, Pub. L. No. 117-328, div. FF, tit. III (2022)
MEDIA CONTACT
Ms. Natalia Farr
